Intellia Therapeutics (NTLA) plans to cut its workforce by 27% to cuts costs and stop development of NTLA-3001 to treat alpha-1 antitrypsin deficiency-associated lung disease and halt some research-stage programs.
Resources will be focused on NTLA-2002 for hereditary angioedema and nexiguran ziclumeran for transthyretin amyloidosis, the company said Thursday in a statement.
The company expects to incur charges of $8 million in Q1 in its reorganization.
The company ended Q4 with about $862 million in cash and investments. The combination of the cash balance and expected cost savings are expected to provide a cash runway into H1 2027, Intellia said.
Laura Sepp-Lorenzino will move from her role as chief scientific officer to become a senior scientific adviser before retiring on Dec. 31, the company said.
Birgit Schultes will be chief scientific officer, effective Monday, after leading immunology and cell therapy since 2017, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.